Provided by Tiger Trade Technology Pte. Ltd.

Black Diamond Therapeutics, Inc.

2.18
+0.06503.08%
Volume:198.81K
Turnover:432.34K
Market Cap:124.60M
PE:5.58
High:2.24
Open:2.21
Low:2.14
Close:2.11
52wk High:4.94
52wk Low:1.20
Shares:57.29M
Float Shares:39.24M
Volume Ratio:0.92
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:22.88%
ROA:9.35%
PB:1.11
PE(LYR):5.58

Loading ...

Black Diamond Therapeutics Inc - Silevertinib Shows 60% Orr and 86% CNS Response in 1L Nsclc

THOMSON REUTERS
·
Dec 03, 2025

Black Diamond Therapeutics Inc: Pfs Data for 1L Nsclc Patients Expected in Q2 2026

THOMSON REUTERS
·
Dec 03, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

GlobeNewswire
·
Dec 03, 2025

Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results

Reuters
·
Dec 03, 2025

Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
Nov 20, 2025

U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler

Reuters
·
Nov 18, 2025

Black Diamond Therapeutics Inc : Piper Sandler Assumes Coverage With Overweight Rating; Target Price $9

THOMSON REUTERS
·
Nov 18, 2025

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

TIPRANKS
·
Nov 18, 2025

BRIEF-Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
Nov 14, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)

TIPRANKS
·
Nov 13, 2025

Black Diamond Therapeutics Reports Positive Financial Turnaround

TIPRANKS
·
Nov 11, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

3 Promising Penny Stocks With Market Caps Below $600M

Simply Wall St.
·
Nov 08, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Black Diamond Therapeutics to Present at Piper Sandler Healthcare Conference

Reuters
·
Nov 07, 2025

Black Diamond narrows Q3 net loss as R&D costs drop

Reuters
·
Nov 06, 2025

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

TIPRANKS
·
Nov 06, 2025

Black Diamond Therapeutics sees cash runway into 4Q27

TIPRANKS
·
Nov 06, 2025

Black Diamond Therapeutics Q3 Basic EPS USD -0.15

THOMSON REUTERS
·
Nov 06, 2025

Black Diamond Therapeutics Q3 Cash & Investments USD 135.5 Million

THOMSON REUTERS
·
Nov 06, 2025